secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001099800-21-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance
------------------------------------------------------------------------------

- Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.
- TAVR sales $902M (+52% reported, +48% underlying); FY2021 TAVR growth guidance raised to ~20%.
- Full-year 2021 sales guidance raised to $5.2–$5.4B (from $4.9–$5.3B); adjusted EPS guided to high end of $2.07–$2.27.
- Q3 2021 guidance: sales $1.29–$1.37B, adjusted EPS $0.50–$0.56.
- Free cash flow $457M; cash $2.6B; repurchased 1.3M shares for $112M in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/0001099800-21-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/ew-20210729.htm
  HTML page:      https://secwatch.observer/filing/0001099800-21-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer